ArchiveSCV
the-signal.com. The Santa Clarita Valley Signal. Back to the collection.

· signalscv.com, Wayback capture

MannKind reports Q1 results

MannKind of Santa Clarita reported Thursday that expenses across the board declined significantly in the first quarter of 2015, compared to the same period in 2014, as a result of the FDA’s approval of Afrezza last year.

First quarter operating expenses declined nearly 48 percent to $21.7 million. Research and development expenses declined 64.2 percent to $9.4 million.

General and administrative expenses declined 31.2 percent to $10.5 million in the first quarter, compared to the prior year.

Net losses for the quarter were $30.7 million – an improvement, however, over net losses of $52.1 million the prior year.

MannKind’s portion of the loss sharing arrangement with Sanofi was $12.4 million. The biomedical company entered into a partnership with Paris-based Sanofi last year, to market and distribute the diabetes treatment inhaler Afrezza.

For the period ending March 31, MannKind recorded $7.1 million in Afrezza shipments.

← Back to 2015

About this record

How it was held, read and classified

Record details

Morris ID
136707
System
Morris section CMS (/section/…/article/… and /archives/…)
Reading copy
signalscv.com
Chosen by: only copy held. On this copy: words 144 (e-mail addresses counted as one token); reader comments 0 (counted, not reproduced here); images 0.
Extracted by
section_cms:articlebody_span
signal-extract/0.15 (2026-11-16)

Other copies

Held
None. The holding has this article from one host only.

How it was classified

Label
clearly-local
Judgment
A machine’s (recorded as machine), kept as one so it can be revisited.
Classifier
signal-localclass/0.7 (2026-11-12)
Local signals
  • url:section_24_local
  • byline:staff_marker [Signal Staff]
  • text:valley_names [1 distinct/1 mentions: Santa Clarita]
National signals
none fired
Scores
local 7, national 0